| Literature DB >> 30131342 |
Linda M Haugaard-Kedström1,2, Han Siean Lee1, Maryon V Jones1, Angela Song1, Vishaal Rathod1, Mohammed Akhter Hossain3,4, Ross A D Bathgate5,6, K Johan Rosengren7.
Abstract
The neuropeptide relaxin-3 and its receptor relaxin family peptide receptor-3 (RXFP3) play key roles in modulating behavior such as memory and learning, food intake, and reward seeking. A linear relaxin-3 antagonist (R3 B1-22R) based on a modified and truncated relaxin-3 B-chain was recently developed. R3 B1-22R is unstructured in solution; thus, the binding conformation and determinants of receptor binding are unclear. Here, we have designed, chemically synthesized, and pharmacologically characterized more than 60 analogues of R3 B1-22R to develop an extensive understanding of its structure-activity relationships. We show that the key driver for affinity is the nonnative C-terminal Arg23 Additional contributors to binding include amino acid residues that are important also for relaxin-3 binding, including Arg12, Ile15, and Ile19 Intriguingly, amino acid residues that are not exposed in native relaxin-3, including Phe14 and Ala17, also interact with RXFP3. We show that R3 B1-22R has a propensity to form a helical structure, and modifications that support a helical conformation are functionally well-tolerated, whereas helix breakers such as proline residues disrupt binding. These data suggest that the peptide adopts a helical conformation, like relaxin-3, upon binding to RXFP3, but that its smaller size allows it to penetrate deeper into the orthosteric binding site, creating more extensive contacts with the receptor.Entities:
Keywords: G protein-coupled receptor (GPCR); R3 B1-22R; RXFP3; alanine scan; antagonist; neuropeptide; peptide conformation; peptide interaction; peptide stapling; relaxin-3
Mesh:
Substances:
Year: 2018 PMID: 30131342 PMCID: PMC6187623 DOI: 10.1074/jbc.RA118.002611
Source DB: PubMed Journal: J Biol Chem ISSN: 0021-9258 Impact factor: 5.157